Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 63, Issue 1, Pages 96-99Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.121.262206
Keywords
myeloproliferative neoplasms; CXCR4; molecular imaging; PET; theranostics
Ask authors/readers for more resources
This study investigated the feasibility of CXCR4-directed imaging with Ga-68-pentixafor PET/CT in MPNs. The results showed that this method can noninvasively detect and quantify the extent of disease involvement in MPNs, and the dynamic changes in CXCR4 expression corresponded with treatment response.
C-X-C motif chemokine receptor 4 (CXCR4) is an attractive target for cancer diagnosis and treatment, as it is overexpressed in many solid and hematologic malignancies. This study investigated the feasibility of CXCR4-directed imaging with PET/CT using Ga-68-pentixafor to visualize and quantify disease involvement in myeloproliferative neoplasms (MPNs). Methods: Twelve patients with MPNs (4 with primary myelofibrosis, 6 with essential thrombocythemia, and 2 with polycythemia vera) and 5 controls underwent Ga-68-pentixafor PET/CT. Imaging findings were compared with immunohistochemical stainings, laboratory data, and splenic volume. Results: Ga-68-pentixafor PET/ CT was visually positive in 12 of 12 patients, and CXCR4 target specificity could be confirmed by immunohistochemical staining. A significantly higher tracer uptake could be detected in the bone marrow of MPN patients (SUVmean, 6.45 +/- 2.34 vs. 4.44 +/- 1.24). Dynamic changes in CXCR4 expression determined by Ga-68-pentixafor PET/CT corresponded with treatment response. Conclusion: Ga-68-pentixafor PET/CT represents a novel diagnostic tool to noninvasively detect and quantify the extent of disease involvement in MPNs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available